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C4.3
Surgery
C4.3.1
Indications
Immediate surgical revascularisation is indicated in
the profoundly ischaemic limb, that is, class lIb and
early class III (see Figure 17) (see C 2.3, Clinical
Classification of Acute Limb Ischaemia, p SI22) .
Catheter embolectomy is also usually preferred for
emboli to a nonatherosclerotic limb. Emboli in non-
atherosclerotic limbs usually result in profound
ischaemia (lIb or III) and therefore are best treated sur-
gically. In considering operative versus percutaneous
revascularisation, it must be recognised that the time
from the decision to operate until reperfusion may be
substantially longer than anticipated because of fac-
tors outside of the surgeons' control (eg, operating
theatre availability, anaesthesia preparation, technical
details of the operation).
Recommendation 60: Indications for surgery in
acute limb ischaemia
Immediately limb-threatening ischaemia (class lIb
and early class III) is preferentially treated surgi-
cally.
C 4.3 .2
Surgical Technique
Emboli are preferentially removed surgically if they
are lodged proximally in the limb or if there is reason
to suspect that they have impacted on a nonathero-
sclerotic limb. When no further clot can be retrieved,
an angiogram or angioscopy should be performed to
visualise distal vessels. In up to one third of cases,
there is residual thrombus,' which, because of the con-
tinuing occlusion of the run-off vessels, can lead to
failure.P Some form of intraoperative monitoring of
the adequacy of clot removal is required. The most
common of these is "completion" angiography per-
formed before arteriotomy closure. Fibreoptic
endoscopy also has been advocated for this purpose
but is probably inadequate for distal artery visualisa-
tion.
Distal clot may be treated by intraoperative throm-
bolysis with instillation of high doses of thrombolytic
agents for a brief period followed by irrigation or
additional passages of the balloon catheter. Repeat
angiography followed by clinical and Doppler exami-
nation of the patient should be performed on the oper-
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ating table. This will determine whether the procedure
has been adequate or whether add itional attempts at
distal clot removal or even bypass are needed.
Percutaneous clot aspiration or thrombolysis, at a later
point when the risk of haemorrhage is reduced, also
has been recommended. It is important to continue
efforts until there is reasonable assurance of a viable
extremity. As a last resort, isolated limb perfusion
technique has been advocated to reduce the systemic
effects of thrombolysis.w
Unlike embolism, in arterial thrombosis, an under-
lying local lesion must be sought after clot extraction,
in addition to residual thrombus. Often this may be
suspected from the tactile sensations and need for
deflation at points during the withdrawal of the inflat-
ed balloon catheter. Here completion angiography
will help decide between proceeding with a bypass or
PTA. Fortunately, arterial thrombosis superimposed
on an already narrowed artery will ordinarily cause a
less severe degree of ischaemia because of predevel-
oped collaterals. Under these circumstances, patients
may not be operated on initially but will undergo
catheter-directed lytic therapy.
Recommendation 61: Perioperative angiography
Unless there is good evidence that adequate circu-
lation has been restored, eg, bounding pulses, reac-
tive hyperaemia, or excellent distal Doppler signals,
intraoperative angiography should be performed to
identify any residual occlusion or critical arterial
lesions requiring further treatment. Imaging
should be repeated so that complete clot clearance
can be demonstrated.
C 4.4
Results of Surgical and Endovascular Procedures
for Acute Limb Ischaemia
Catheter-directed thrombolysis (COT) has become a
commonly employed technique in the treatment of
ALI. In the first randomised, controlled small study of
surgery versus thrombolysis in patients with ALI (of
duration between 24 hours and 14 days), the L-month
limb salvage rates were 87% and 90% for surgery and
thrombolysis, respectively> Secondary procedures
were, however, required in a considerable number of
cases. Between 1994 and 1996, three large, prospective,
randomised trials were reported that focused on the
comparison of COT and surgical revascularisation
(SR) for treatment of acute limb ischaemiaP.s Other
studies have been reported but are not considered
here because in some cases there was a lack of
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prospective randomisation, selection bias, or case
exclusions.9.10.11.12.13.1~.15
Limb salvage and mortality rates are recognised as
the most important outcome, and the I-year data are
summarised in Table 36. Comparison of these studies
is limited by certain differences in protocol and case
mix (eg, acute vs subacute or chronic limb ischaemia;
thrombotic vs embolic occlusion; native vs bypass graft
occlusion; proximal vs distal occlusions). End points in
each of the studies also vary: the Rochester study used
"event-free survival"; the STILE trial used "composite
clinical outcome"; and the TaPAS study used "arterial
recanalisation and extent of lysis ." Only the Rochester
trial showed any advantage for COT by primary end
points. The STILE trial favoured surgery, and the
TaPAS study showed no difference. Other advantages
for COT could only be shown by post hoc subgroup
analysis. Moreover, none of the three published reports
contain follow-up data regarding those patients treat-
ed concurrently at the participating institutions but not
enrolled in the three studies; such data would help to
determine the extent to which patients who might
have been considered appropriate candidates for the
respective therapies were not randomised.
In the Rochester study, patients with class II limb-
threatening ischaemia of less than 7 days' duration
were randomly assigned to either COT with urokinase
or SR.6 This included patients with both thrombotic
and embolic occlusions of native arteries and bypass
grafts. Any anatomic lesions were subsequently treat-
ed with balloon angioplasty or surgery, but predomi-
nantly the latter. Although the cumulative limb sal-
vage rates were identical in both groups (82%), the 12-
month mortality rates were markedly higher in the
surgical group (42% vs 16%, P =0.01). This was pri-
marily as a result of the increased frequency of in-hos-
pital cardiopulmonary complications in the surgery
group (49% vs 16%, P = 0.001). This study indicated a
clear survival advantage of thrombolytic therapy in
the characteristically high-risk patients treated acutely
during an episode of truly limb-threatening
ischaemia.
The STILE trial enrolled patients with thrombotic
native artery or bypass graft occlusions of less than 6
months' duration? Unfortunately, close to three quar-
ters of these patients had ischaemia of over 14 days'
duration, and, importantly, the number with class II
limb -threatening ischaemia was negligible. According
to prestudy statistical analysis, the trial was originally
designed to include a total of 1,000 patients. However,
the interim analysis showed a highly significant dif-
ference at 1 month in the rate of ongoing/recurrent
ischaemia (54.0% vs 25.7%, P < 0.001) and the com-
posite clinical outcome (61.7% vs 36.1%, P < 0.001) in
the thrombolytic group compared with the surgical
group. The trial was therefore terminated premature-
ly. A critical feature of this and the other trials was the
higher-than-anticipated incidence of failure to suc- ·
cessfully traverse the occlusion with a guidewire (28%
of patients), obviating lytic therapy. These patients
were then considered treatment failures on an inten-
tion-to-treat basis. Whether these strictly monitored
trial data are closer to the truth than clinical reports
have suggested has been debated.
The disappointing overall results have led to the
STILE data often being presented toithoui the higher
rates of ongoing or recurrent ischaemia and major
complications for thrombolysis and with postran-
domisation stratification into "before" and "after" 14
days of ischaemia. The cut-off of 14 days is arbitrary
(and probably unrealistic) in discussing the outcome
of "acute" limb ischaemia. The results of thrombolysis
are not statistically different between the two periods
(although the results of surgery performed sooner
than 14 days being much worse than when it is per-
formed after more than 14 days improves the compar-
ison in favour of thrombolysis for the early period).
Nevertheless, the early period presents a more reason-
able view of thrombolysis in the acute setting.
In the trials discussed here, very few patients
enrolled had acute limb ischaemia category II or
greater as defined in Recommendation 45 and
Recommendation 47. The frequent citing of these ref-
erences in discussions on ALI has lead to a review of
Table 36: Comparison of catheter-directed thrombolysis (COT) and surgical revascularisation (SR) in treatment of limb
ischaemia
Results at
Catheter-Directed Thrombolysis (COT)
Patients Limb salvage Mortality
(%) (%)
Surgical Revascularisation (SR)
Patients Limb salvage Mortality
('Yo) (%)
Rochester-
STILEt
TOPAS~
12mo
6mo
12mo
57
246
144
82
88.2
82.7
16
6.5
13.3
57
141
54
82
89.4
8U
42
8.5
15.7
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Table 37: Summary of major findings of the retrospective analysis" of the STILE trial data,,1.
Time End point Surgery (%) CDT(%) P
Data group
All patients 1 mo Composite clinical outcome 36.1 61.7 <0.001
(morbidity, recurrent ischaemia,
complications)
All patients 1 mo Ongoing/recurrent ischaemia 25.7 54.0 <0.001
Subgroup analysis
All vessels <14 days 6mo Death, amputation 37.5 15.3 0.01
All vessels >14 days 6mo Death, amputation 9.9 17.8 0.08
Native artery <14 days 12mo Mortality 18.8 6.3 NS
Native artery <14 days 12mo Major amputation 0 6.3 NS
Native artery (all duration) 1 mo Ongoing/recurrent ischaemia 23.5 54.7 <0.001
Native artery (all duration) 1 mo Major amputation 2.0 4.1 0.364
"Intent-to-treat analysis. 28% technical failure (failure to traverse occlusion) with CDT.
the results as follows (accepting that they may apply
to only a small subset of patients with ALI): patients
with less than 14 days' duration of ischaemia had
fewer deaths or amputations combined at 6 months in
the COT group compared with the SR group (15.3%vs
37.5%, P = 0.01). Even with this finding, the combined
clinical outcome favoured surgery. This trend was
reversed in the group of patients presenting with
"chronic" symptoms (>14 days' duration), although
the difference was not statistically significant (17.8%
vs 9.9%, P = 0.08). Subgroup analysis disclosed that,
among patients with native artery occlusions (at 30
days), those treated with COT had a greater incidence
of ongoing/recurrent ischaemia (54.7% vs 23.5%, P <
0.001) and a worse limb salvage rate (4.1% vs 2.0%
major amputation, p = 0.364) compared with the sur-
gical group. Weaver et al carried out a further sub-
group analysis of STILE patients with native artery
occlusions. In patients with less than 14 days' duration
of ischaemia, at 1 year by intent-to-treat, the mortality
rate was less in the COT group (6.3% vs. 18.8%, NS),
but the amputation rate was higher compared with
surgery (6.3% vs 0%, NS). The persisting/recurrent
ischaemia and major complications were higher for
thrombolysis. Thus, in the STILE trials, there seems to
be a trade-off between mortality and amputation and
persistent/recurrent ischaemia, and major morbidity
(Table 37).
The TaPAS trial investigated patients with limb
ischaemia of less than 14 days' duration caused by
embolic and thrombotic native artery and bypass graft
occlusions. The phase I report emphasised the com-
parison of three different dosages (2,000IV/min, 4,000
IV/min, 6,000 IV/min) of recombinant urokinase.
Primary end points were recanalisation and extent of
clot lysis on the arteriogram 4 hours after the infusion.
There was no significant difference among the three
urokinase dosages in achieving recanalisation. The
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dose of 4,000 IV/min urokinase was shown to be the
safest, with the lowest incidence of haemorrhagic
events.
Comparison of COT for the different urokinase
dosages showed no significant difference in amputa-
tion-free survival rates and no advantage over sur-
gery. The actual procedure performed was less exten-
sive than predicted in 49.7% of COT patients as com-
pared with 13.8% of SR patients. However, in the pro-
cedure severity scale used, thrombectomy or PTA
were considered lesser procedures than digital or
transmetatarsal amputation. Thrombectomy with
revision/repair of an existing bypass graft was con-
sidered a lesser procedure than placement of a new
bypass. A subsequent analysis of the TaPAS trial
determined which patient factors predicted successful
therapy in terms of amputation-free survival. Of 28
variables, eight were found to be predictive using a
Cox proportional hazards multifactor analysis. None
of these eight favoured one form of treatment over
another. The length of occlusion, however, predicted
whether a patient would fare better with thrombolysis
or surgery, with occlusions shorter than 30 cm doing
better with surgery and those longer than 30 ern doing
better with CDTY
The only statistically significant overall survival
benefit of COT was found in the Rochester trial and
was related primarily to patients with cardiac disease.s
These findings were interpreted to suggest that COT
may be safer for such patients and can achieve equiv-
alent limb salvage. The magnitude of the surgical pro-
cedure was reduced in approximately 50% of patients
in whom COT constituted initial therapy even though
treatment of underlying lesions was predominantly
surgical. The type of agent used-urokinase, recombi-
nant urokinase, or recombinant tissue plasminogen
activator-was not shown in the various trials to play
a role in determining the results of COT. Bleeding
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complications in patients treated with COT occurred
in 5% to 20% of patients, but in most this was cate-
gorised as minor. No predictors of major bleeding
could be identified by patient characteristics, although
a fibrinogen level less than 150 mg/dL increased the
likelihood of major bleeding.
A meta-analysis reviewing two of these trials has
shown an advantage in limb salvage and mortality for
catheter-directed thrombolysis.P Reviewing the data
from the few randomised, prospective studies in ALI,
COT may be viewed as offering advantages when
compared with surgical revascularisatlon in terms of
reduced mortality rates and complexity of the surgical
procedure required in exchange for a higher rate of
failure to avoid persistent or recurrent ischaemia,
major complications, and ultimate risk of amputation.
In addition, it appears that reperfusion with COT is
achieved at a lower pressure and may reduce the risk
of reperfusion injury.ISThus, if the limb is not imme-
diately or irreversibly threatened, COT offers a lower-
risk opportunity for arterial revascularisation.'? Using
this approach, the underlying lesions can be further
defined by angiography, and the appropriate percuta-
neous or surgical revascularisation procedure can be
performed. Therefore, it seems reasonable to recom-
mend COT as initial therapy in these particular set-
tings, to be potentially followed by surgical revascu-
larisation as needed (see Recommendation 57, p 5130).
Critical Issue 22: Comparison of therapeutic
options for acute limb ischaemia
There is a need for prospective, randomised trials to
rigorously compare catheter-directed thrombolysis
(COT), percutaneous mechanical thrombectomy
(PMT), percutaneous aspiration thromboembolec-
tomy (PAT), intraoperative thrombolysis, and surgi-
cal revascularisation (5R) for the treatment of
thrombotic versus embolic occlusions of native
arteries versus bypass grafts, and that arc specifi-
cally designed to include determination of cost-
effectiveness and long-term outcome, including
functional status.
Critical Issue 23: Further factors when considering
choice of treatment for acute limb ischaemia
There is a need, when considering choice of treat-
ment for acute limb ischaemia, for further studies
to obtain additional information concerning:
• the length of time that the lower extremity will
tolerate profound ischaemia without permanent
damage
• The effect of the duration of the occlusion on the
success of recanalisation
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